Biotech News

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Lexicon Pharmaceuticals (LXRX)Lexicon PharmaceuticalsEarnings

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/ . Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on the Lexicon website.

About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com .

For Investor and Media Inquiries : Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. [email protected]

Related news

Lexicon Pharmaceuticals

Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases. Sotagliflozin Franchise Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application...

Recent company news

Stock data

Close
2.36 USD
Market cap
839.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States